Laquinimod Beneficial in Reducing Multiple Sclerosis Relapse Rate in Clinical Trials
Links shared publicly online about this topic.
- 366total visits
Laquinimod Beneficial in Reducing Multiple Sclerosis Relapse Rate in Clinical Trials
Multiple sclerosis is an autoimmune disease characterized by symptomatic episodes that alternate with periods of remission. The amount of disability ...
View full resource at emaxhealth.com
Tags: Multiple Sclerosis, Autoimmune Disease, Disease and Condition, Clinical Trial, Disability, disease
Most Recently Shared on April 14, 2011 at 2:20 pm By:
Laquinimod Beneficial in Reducing Multiple Sclerosis Relapse Rate in Clinical Trials http://bit.ly/fQ3INT
Teva shares fall after MS drug misses study goal - Yahoo! News
news.yahoo.com — “Read 'Teva shares fall after MS drug misses study goal' on Yahoo! News. Teva Pharmaceutical Industries Ltd. said its experimental drug laquinimod, an oral treatment for multiple sclerosis, did not reduce patients' annual relapse rate in a late-stage clinical trial.” View full resource at news.yahoo.com
Most Recently Shared on August 1, 2011 at 8:07 pm By:
Teva shares fall after MS drug misses study goal: Teva Pharmaceutical Industries Ltd. said its experimental dru... http://yhoo.it/pqbSba
Advertisement
